Search

Your search keyword '"Davies, Faith E"' showing total 2,096 results
Start Over Author "Davies, Faith E"
2,096 results on '"Davies, Faith E"'

2. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens

Author

Maura, Francesco, Boyle, Eileen M., Coffey, David, Maclachlan, Kylee, Gagler, Dylan, Diamond, Benjamin, Ghamlouch, Hussein, Blaney, Patrick, Ziccheddu, Bachisio, Cirrincione, Anthony, Chojnacka, Monika, Wang, Yubao, Siegel, Ariel, Hoffman, James E., Kazandjian, Dickran, Hassoun, Hani, Guzman, Emily, Mailankody, Sham, Shah, Urvi A., Tan, Carlyn, Hultcrantz, Malin, Scordo, Michael, Shah, Gunjan L., Landau, Heather, Chung, David J., Giralt, Sergio, Zhang, Yanming, Arbini, Arnaldo, Gao, Qi, Roshal, Mikhail, Dogan, Ahmet, Lesokhin, Alexander M., Davies, Faith E., Usmani, Saad Z., Korde, Neha, Morgan, Gareth J., and Landgren, Ola

Published
2023
Full Text
View/download PDF

3. How to provide the needed protection from COVID-19 to patients with hematologic malignancies

Author

Ribas, Antoni, Dhodapkar, Madhav V, Campbell, Katie M, Davies, Faith E, Gore, Steven D, Levy, Ronald, and Greenberger, Lee M

Subjects
Prevention, Immunization, Cancer, Vaccine Related, Emerging Infectious Diseases, Patient Safety, Hematology, Good Health and Well Being, Adult, COVID-19, COVID-19 Vaccines, Hematologic Neoplasms, Humans, Immunization, Secondary, SARS-CoV-2
Abstract

Patients with hematologic malignancies are particularly vulnerable to COVID-19 infections, and upon a pooled data analysis of 24 publications, there is evidence that they have suboptimal antibody responses to COVID-19 vaccination and boosters. To provide them the needed additional protection from COVID-19, it is imperative to achieve a 100% full immunization rate in health care workers and adult caretakers, and to foster research to test higher doses and repeated rounds of COVID-19 vaccines and the use of passive immune prophylaxis and therapy.

Published
2021

6. Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial

Author

Jones, John R., Cairns, David A., Menzies, Tom, Pawlyn, Charlotte, Davies, Faith E., Sigsworth, Rachel, Brioli, Annamaria, Jenner, Matthew W., Kaiser, Martin F., Olivier, Catherine, Reed, Molly, Drayson, Mark T., Owen, Roger G., Boyd, Kevin D., Cook, Gordon, Morgan, Gareth J., and Jackson, Graham H.

Published
2023
Full Text
View/download PDF

8. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

Author

Thompson, Michael A., Boccadoro, Mario, Leleu, Xavier, Vela-Ojeda, Jorge, van Rhee, Frits, Weisel, Katja C., Rifkin, Robert M., Usmani, Saad Z., Hájek, Roman, Cook, Gordon, Abonour, Rafat, Armour, Mira, Morgan, Kathryn E., Yeh, Su-Peng, Costello, Caitlin L., Berdeja, Jesus G., Davies, Faith E., Zonder, Jeffrey A., Lee, Hans C., Omel, Jim, Spencer, Andrew, Terpos, Evangelos, Hungria, Vania T.M., Puig, Noemi, Fu, Chengcheng, Ferrari, Renda H., Ren, Kaili, Stull, Dawn Marie, and Chari, Ajai

Published
2023
Full Text
View/download PDF

9. INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma

Author

Costello, Caitlin, Davies, Faith E, Cook, Gordon, Vela-Ojeda, Jorge, Omel, Jim, Rifkin, Robert M, Berdeja, Jesus, Puig, Noemi, Usmani, Saad Z, Weisel, Katja, Zonder, Jeffrey A, Terpos, Evangelos, Spencer, Andrew, Leleu, Xavier, Boccadoro, Mario, Thompson, Michael A, Romanus, Dorothy, Stull, Dawn M, and Hungria, Vania

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Comparative Effectiveness Research, Hematology, Orphan Drug, Rare Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Follow-Up Studies, Humans, International Agencies, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Prospective Studies, Quality of Life, Treatment Outcome, Young Adult, multiple myeloma, observational study, treatment, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

With the introduction of new drugs with different mechanisms of action, multiple myeloma (MM) patients' outcomes have improved. However, the efficacy seen in clinical trials is often not seen in real-world settings and data on the effectiveness of MM therapies are needed. INSIGHT MM is a prospective, global, non-interventional, observational study that is enrolling approximately 4200 patients with newly diagnosed or relapsed/refractory MM, making it the largest study of its kind to date. The study aims to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapies chosen, clinical outcomes (response, treatment duration, time-to-next-therapy, progression-free and overall survival), safety, healthcare resource utilization and quality of life. One interim analysis has been conducted to date; current accrual is approximately 3094 patients. Trial registration number: NCT02761187.

Published
2019

12. Chromothripsis as a pathogenic driver of multiple myeloma

Author

Maura, Francesco, Boyle, Eileen M., Rustad, Even H., Ashby, Cody, Kaminetzky, David, Bruno, Benedetto, Braunstein, Marc, Bauer, Michael, Blaney, Patrick, Wang, Yubao, Ghamlouch, Hussein, Williams, Louis, Stoeckle, James, Davies, Faith E., Walker, Brian A., Maclachlan, Kylee, Diamond, Ben, Landgren, Ola, and Morgan, Gareth J.

Published
2022
Full Text
View/download PDF

14. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups

Author

Boyle, Eileen M., Rosenthal, Adam, Ghamlouch, Hussein, Wang, Yan, Farmer, Phillip, Rutherford, Michael, Ashby, Cody, Bauer, Michael, Johnson, Sarah K., Wardell, Christopher P., Wang, Yubao, Hoering, Antje, Schinke, Carolina, Thanendrarajan, Sharmilan, Zangari, Maurizio, Barlogie, Bart, Dhodapkar, Madhav V., Davies, Faith E., Morgan, Gareth J., van Rhee, Frits, and Walker, Brian A.

Published
2022
Full Text
View/download PDF

15. Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length

Author

Boyle, Eileen M., Williams, Louis, Blaney, Patrick, Ashby, Cody, Bauer, Michael, Walker, Brian A., Ghamlouch, Hussein, Choi, Jinyoung, Perrial, Emeline, Wang, Yubao, Caro, Jessica, Stoeckle, James H., Arbini, Arnaldo, Kaminetzky, David, Braunstein, Marc, Bruno, Benedetto, Razzo, Beatrice, Diamond, Benjamin, Maclachlan, Kylee, Maura, Francesco, Landgren, Ola, Litke, Rachel, Fegan, Christopher D., Keats, Johnathan, Auclair, Daniel, Davies, Faith E., and Morgan, Gareth J.

Published
2022
Full Text
View/download PDF

17. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes

Author

Bustoros, Mark, Anand, Shankara, Sklavenitis-Pistofidis, Romanos, Redd, Robert, Boyle, Eileen M., Zhitomirsky, Benny, Dunford, Andrew J., Tai, Yu-Tzu, Chavda, Selina J., Boehner, Cody, Neuse, Carl Jannes, Rahmat, Mahshid, Dutta, Ankit, Casneuf, Tineke, Verona, Raluca, Kastritis, Efstathis, Trippa, Lorenzo, Stewart, Chip, Walker, Brian A., Davies, Faith E., Dimopoulos, Meletios-Athanasios, Bergsagel, P. Leif, Yong, Kwee, Morgan, Gareth J., Aguet, François, Getz, Gad, and Ghobrial, Irene M.

Published
2022
Full Text
View/download PDF

21. Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial

Author

Croft, James, Ellis, Sidra, Sherborne, Amy L., Sharp, Kim, Price, Amy, Jenner, Matthew W., Drayson, Mark T., Owen, Roger G., Chown, Sally, Lindsay, Jindriska, Karunanithi, Kamaraj, Hunter, Hannah, Gregory, Walter M., Davies, Faith E., Morgan, Gareth J., Cook, Gordon, Atanesyan, Lilit, Savola, Suvi, Cairns, David A., Jackson, Graham, Houlston, Richard S., and Kaiser, Martin F.

Published
2021
Full Text
View/download PDF

23. Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.

Author

Lee, Hans C., Ramasamy, Karthik, Macro, Margaret, Davies, Faith E., Abonour, Rafat, van Rhee, Frits, Hungria, Vania T. M., Puig, Noemi, Ren, Kaili, Silar, Jiri, Enwemadu, Victoria, Cherepanov, Dasha, and Leleu, Xavier

Subjects
MULTIPLE myeloma, PROTEASOME inhibitors, LENALIDOMIDE, BORTEZOMIB, REFRACTORY materials, PROGRESSION-free survival
Abstract

Objectives: To characterize the impact of prior exposure and refractoriness to lenalidomide or proteasome inhibitors (PIs) on the effectiveness and safety of ixazomib–lenalidomide–dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM). Methods: INSURE is a pooled analysis of adult RRMM patients who had received IRd in ≥2 line of therapy from three studies: INSIGHT MM, UVEA‐IXA, and REMIX. Results: Overall, 391/100/68 were lenalidomide‐naïve/−exposed/−refractory and 37/411/110 were PI‐naïve/−exposed/−refractory. Median duration of therapy (DOT) was 15.3/15.6/4.7 months and median progression‐free survival (PFS) was 21.6/25.8/5.6 months in lenalidomide‐naïve/exposed/refractory patients. Median DOT and PFS in PI‐naïve/exposed/refractory patients were 20.4/15.2/6.9 months and not reached/19.8/11.4 months, respectively. The proportion of lenalidomide‐naïve/exposed/refractory patients in INSIGHT and UVEA‐IXA who discontinued a study drug due to adverse events (AEs) was ixazomib, 31.6/28.2/28.0% and 18.6/6.7/10.5%; lenalidomide, 21.9/28.2/16.0% and 16.1/6.7/10.5%; dexamethasone, 18.4/20.5/16.0% and 10.6/0/10.5%, respectively. The proportion of PI‐naïve/exposed/refractory patients in INSIGHT and UVEA‐IXA who discontinued a study drug due to AEs was: ixazomib, 44.4/28.8/27.8% and 22.2/16.7/15.7%; lenalidomide, 33.3/22.0/19.4% and 16.7/15.9/11.8%; dexamethasone, 33.3/17.4/16.7% and 16.7/9.5/7.8%, respectively. REMIX AE discontinuation rates were unavailable. Conclusion: IRd appeared to be effective in RRMM patients in routine clinical practice regardless of prior lenalidomide or PI exposure, with better outcomes seen in lenalidomide‐ and/or PI‐nonrefractory versus refractory patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

Author

Ghobrial, Irene M., primary, Gormley, Nicole, additional, Kumar, Shaji K., additional, Mateos, Maria-Victoria, additional, Bergsagel, P. Leif, additional, Chesi, Marta, additional, Dhodapkar, Madhav V., additional, Dispenzieri, Angela, additional, Fonseca, Rafael, additional, Getz, Gad, additional, Kastritis, Efstathios, additional, Kristinsson, Sigurdur Y., additional, Martinez-Climent, Jose Angel, additional, Manier, Salomon, additional, Marinac, Catherine R., additional, Maura, Francesco, additional, Morgan, Gareth J., additional, Davies, Faith E., additional, Nadeem, Omar, additional, Nuvolone, Mario, additional, Paiva, Bruno, additional, O’Donnell, Elizabeth, additional, Prosper, Felipe, additional, Shah, Urvi A., additional, Sklavenitis-Pistofidis, Romanos, additional, Sperling, Adam S., additional, Vassiliou, George S., additional, Munshi, Nikhil C., additional, Castle, Philip E., additional, Anderson, Kenneth C., additional, and San Miguel, Jesus F., additional

Published
2024
Full Text
View/download PDF

29. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma

Author

Boyle, Eileen M., Deshpande, Shayu, Tytarenko, Ruslana, Ashby, Cody, Wang, Yan, Bauer, Michael A., Johnson, Sarah K., Wardell, Christopher P., Thanendrarajan, Sharmilan, Zangari, Maurizio, Facon, Thierry, Dumontet, Charles, Barlogie, Bart, Arbini, Arnaldo, Rustad, Even H., Maura, Francesco, Landgren, Ola, Zhan, Fenghuang, van Rhee, Frits, Schinke, Carolina, Davies, Faith E., Morgan, Gareth J., and Walker, Brian A.

Published
2021
Full Text
View/download PDF

31. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

Author

Jackson, Graham H, Davies, Faith E, Pawlyn, Charlotte, Cairns, David A, Striha, Alina, Collett, Corinne, Waterhouse, Anna, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Wilson, Jamie N, Jenner, Matthew W, Cook, Gordon, Kaiser, Martin F, Drayson, Mark T, Owen, Roger G, Russell, Nigel H, Gregory, Walter M, and Morgan, Gareth J

Published
2019
Full Text
View/download PDF

35. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

Author

Jackson, Graham H, Davies, Faith E, Pawlyn, Charlotte, Cairns, David A, Striha, Alina, Collett, Corinne, Hockaday, Anna, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Jenner, Matthew W, Cook, Gordon, Russell, Nigel H, Kaiser, Martin F, Drayson, Mark T, Owen, Roger G, Gregory, Walter M, and Morgan, Gareth J

Published
2019
Full Text
View/download PDF

37. Somatic Hypermutation in Enhancer Regions Shapes Non-Coding Myeloma Genome, Generating DNA Breaks and Driving Etiology through Mutation and Structural Variation

Author

Blaney, Patrick, primary, Walker, Brian A., additional, Mikulasova, Aneta, additional, Gagler, Dylan, additional, Ziccheddu, Bachisio, additional, Diamond, Benjamin, additional, Wang, Yubao, additional, Hou, Liming, additional, Liu, Sanxiong, additional, Poos, Alexandra Maria, additional, Cirrincione, Anthony, additional, Maclachlan, Kylee H, additional, Mai, Elias K., additional, Goldschmidt, Hartmut, additional, Usmani, Saad Z, additional, Raab, Marc S., additional, Weinhold, Niels, additional, Landgren, Ola, additional, Davies, Faith E., additional, Maura, Francesco, additional, and Morgan, Gareth J., additional

Published
2023
Full Text
View/download PDF

39. Supplementary Spreadsheet S3 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma

Author

Boyle, Eileen M., primary, Blaney, Patrick, primary, Stoeckle, James H., primary, Wang, Yubao, primary, Ghamlouch, Hussein, primary, Gagler, Dylan, primary, Braunstein, Marc, primary, Williams, Louis, primary, Tenenbaum, Avital, primary, Siegel, Ariel, primary, Chen, Xiaoyi, primary, Varma, Gaurav, primary, Avigan, Jason, primary, Li, Alexander, primary, Jinsi, Monica, primary, Kaminetzsky, David, primary, Arbini, Arnaldo, primary, Montes, Lydia, primary, Corre, Jill, primary, Rustad, Even H., primary, Landgren, Ola, primary, Maura, Francesco, primary, Walker, Brian A., primary, Bauer, Michael, primary, Bruno, Benedetto, primary, Tsirigos, Aristotelis, primary, Davies, Faith E., primary, and Morgan, Gareth J., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figure S8 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma

Author

Boyle, Eileen M., primary, Blaney, Patrick, primary, Stoeckle, James H., primary, Wang, Yubao, primary, Ghamlouch, Hussein, primary, Gagler, Dylan, primary, Braunstein, Marc, primary, Williams, Louis, primary, Tenenbaum, Avital, primary, Siegel, Ariel, primary, Chen, Xiaoyi, primary, Varma, Gaurav, primary, Avigan, Jason, primary, Li, Alexander, primary, Jinsi, Monica, primary, Kaminetzsky, David, primary, Arbini, Arnaldo, primary, Montes, Lydia, primary, Corre, Jill, primary, Rustad, Even H., primary, Landgren, Ola, primary, Maura, Francesco, primary, Walker, Brian A., primary, Bauer, Michael, primary, Bruno, Benedetto, primary, Tsirigos, Aristotelis, primary, Davies, Faith E., primary, and Morgan, Gareth J., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table S4 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma

Author

Boyle, Eileen M., primary, Blaney, Patrick, primary, Stoeckle, James H., primary, Wang, Yubao, primary, Ghamlouch, Hussein, primary, Gagler, Dylan, primary, Braunstein, Marc, primary, Williams, Louis, primary, Tenenbaum, Avital, primary, Siegel, Ariel, primary, Chen, Xiaoyi, primary, Varma, Gaurav, primary, Avigan, Jason, primary, Li, Alexander, primary, Jinsi, Monica, primary, Kaminetzsky, David, primary, Arbini, Arnaldo, primary, Montes, Lydia, primary, Corre, Jill, primary, Rustad, Even H., primary, Landgren, Ola, primary, Maura, Francesco, primary, Walker, Brian A., primary, Bauer, Michael, primary, Bruno, Benedetto, primary, Tsirigos, Aristotelis, primary, Davies, Faith E., primary, and Morgan, Gareth J., primary

Published
2023
Full Text
View/download PDF

42. Data from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma

Author

Boyle, Eileen M., primary, Blaney, Patrick, primary, Stoeckle, James H., primary, Wang, Yubao, primary, Ghamlouch, Hussein, primary, Gagler, Dylan, primary, Braunstein, Marc, primary, Williams, Louis, primary, Tenenbaum, Avital, primary, Siegel, Ariel, primary, Chen, Xiaoyi, primary, Varma, Gaurav, primary, Avigan, Jason, primary, Li, Alexander, primary, Jinsi, Monica, primary, Kaminetzsky, David, primary, Arbini, Arnaldo, primary, Montes, Lydia, primary, Corre, Jill, primary, Rustad, Even H., primary, Landgren, Ola, primary, Maura, Francesco, primary, Walker, Brian A., primary, Bauer, Michael, primary, Bruno, Benedetto, primary, Tsirigos, Aristotelis, primary, Davies, Faith E., primary, and Morgan, Gareth J., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Methods S1 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma

Author

Boyle, Eileen M., primary, Blaney, Patrick, primary, Stoeckle, James H., primary, Wang, Yubao, primary, Ghamlouch, Hussein, primary, Gagler, Dylan, primary, Braunstein, Marc, primary, Williams, Louis, primary, Tenenbaum, Avital, primary, Siegel, Ariel, primary, Chen, Xiaoyi, primary, Varma, Gaurav, primary, Avigan, Jason, primary, Li, Alexander, primary, Jinsi, Monica, primary, Kaminetzsky, David, primary, Arbini, Arnaldo, primary, Montes, Lydia, primary, Corre, Jill, primary, Rustad, Even H., primary, Landgren, Ola, primary, Maura, Francesco, primary, Walker, Brian A., primary, Bauer, Michael, primary, Bruno, Benedetto, primary, Tsirigos, Aristotelis, primary, Davies, Faith E., primary, and Morgan, Gareth J., primary

Published
2023
Full Text
View/download PDF

45. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Author

Walker, Brian A., Mavrommatis, Konstantinos, Wardell, Christopher P., Ashby, T. Cody, Bauer, Michael, Davies, Faith E., Rosenthal, Adam, Wang, Hongwei, Qu, Pingping, Hoering, Antje, Samur, Mehmet, Towfic, Fadi, Ortiz, Maria, Flynt, Erin, Yu, Zhinuan, Yang, Zhihong, Rozelle, Dan, Obenauer, John, Trotter, Matthew, Auclair, Daniel, Keats, Jonathan, Bolli, Niccolo, Fulciniti, Mariateresa, Szalat, Raphael, Moreau, Philippe, Durie, Brian, Stewart, A. Keith, Goldschmidt, Hartmut, Raab, Marc S., Einsele, Hermann, Sonneveld, Pieter, San Miguel, Jesus, Lonial, Sagar, Jackson, Graham H., Anderson, Kenneth C., Avet-Loiseau, Herve, Munshi, Nikhil, Thakurta, Anjan, and Morgan, Gareth J.

Published
2018
Full Text
View/download PDF

46. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma

Author

Rasche, Leo, Angtuaco, Edgardo J., Alpe, Terri L., Gershner, Grant H., McDonald, James E., Samant, Rohan S., Kumar, Manoj, Van Hemert, Rudy, Epstein, Joshua, Deshpande, Shayu, Tytarenko, Ruslana, Yaccoby, Shmuel, Hillengass, Jens, Thanendrarajan, Sharmilan, Schinke, Carolina, van Rhee, Frits, Zangari, Maurizio, Walker, Brian A., Barlogie, Bart, Morgan, Gareth J., Davies, Faith E., and Weinhold, Niels

Published
2018
Full Text
View/download PDF

49. Supplemental Figure from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

Author

Dawson, Mark A., primary, Borthakur, Gautam, primary, Huntly, Brian J.P., primary, Karadimitris, Anastasios, primary, Alegre, Adrian, primary, Chaidos, Aristeidis, primary, Vogl, Dan T., primary, Pollyea, Daniel A., primary, Davies, Faith E., primary, Morgan, Gareth J., primary, Glass, Jacob L., primary, Kamdar, Manali, primary, Mateos, Maria-Victoria, primary, Tovar, Natalia, primary, Yeh, Paul, primary, Delgado, Regina García, primary, Basheer, Faisal, primary, Marando, Ludovica, primary, Gallipoli, Paolo, primary, Wyce, Anastasia, primary, Krishnatry, Anu Shilpa, primary, Barbash, Olena, primary, Bakirtzi, Evi, primary, Ferron-Brady, Geraldine, primary, Karpinich, Natalie O., primary, McCabe, Michael T., primary, Foley, Shawn W., primary, Horner, Thierry, primary, Dhar, Arindam, primary, Kremer, Brandon E., primary, and Dickinson, Michael, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

Author

Dawson, Mark A., primary, Borthakur, Gautam, primary, Huntly, Brian J.P., primary, Karadimitris, Anastasios, primary, Alegre, Adrian, primary, Chaidos, Aristeidis, primary, Vogl, Dan T., primary, Pollyea, Daniel A., primary, Davies, Faith E., primary, Morgan, Gareth J., primary, Glass, Jacob L., primary, Kamdar, Manali, primary, Mateos, Maria-Victoria, primary, Tovar, Natalia, primary, Yeh, Paul, primary, Delgado, Regina García, primary, Basheer, Faisal, primary, Marando, Ludovica, primary, Gallipoli, Paolo, primary, Wyce, Anastasia, primary, Krishnatry, Anu Shilpa, primary, Barbash, Olena, primary, Bakirtzi, Evi, primary, Ferron-Brady, Geraldine, primary, Karpinich, Natalie O., primary, McCabe, Michael T., primary, Foley, Shawn W., primary, Horner, Thierry, primary, Dhar, Arindam, primary, Kremer, Brandon E., primary, and Dickinson, Michael, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results